Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share ownership changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The only material change reported is a movement in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on August 26, 2005. The number of Ordinary Share ADRs held by the fund increased from 18,413,433 to 18,486,609. This transaction occurred at an average price of $47.82.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for current and former employees. Two directors, Dr. J P Garnier and Dr. T Yamada, are identified as potentially interested in the shares held in the fund in the same capacity as other employees.
Key Facts for Investor Verification
- The increase in ADR holdings (73,176 shares) was driven by a fund movement, not a direct purchase by the directors.
- Directors Dr. J P Garnier and Dr. T Yamada have a potential interest in the fund's holdings but are not the sole beneficiaries.
- The transaction was executed at an average price of $47.82 per ADR.
- This filing is a compliance notification under Disclosure Rule 3.1.4R(1)(b) and does not reflect operational or financial results.